Investor relations

Investor relations

Fourth quarter and full year results 2014

5th February 2015, London

AstraZeneca will announce fourth quarter and full year results for 2014 on Thursday 5th February 2015. Presentations will be made by Pascal Soriot, Chief Executive Officer; Marc Dunoyer, Chief Financial Officer; Briggs Morrison, EVP Global Medicines Development and Luke Miels EVP GPPS, and will be followed by a live question and answer session.p>

View event details


Accounting for the US Branded Pharmaceutical Fee

 Download information here (PDF 89kb)


Latest downloads

AstraZeneca Investor Day

18 November 2014

Third quarter and nine months results 2014

6 November 2014

European Society for Medical Oncology (ESMO) 2014

28 September 2014

Second quarter and half year results 2014

31 July 2014


Annual Report 2013

AstraZeneca Annual Report 2013

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to push the boundaries of science and deliver medicines that transform the lives of people around the world.


Currency guidance 2014

In order to help analysts and investors estimate the impact of changing exchange rates on sales and earnings, the Company provides an annual 'currency sensitivity guide', alongside the rates upon which its earnings guidance is based.

The latest guide, intended to help estimate the impact of currency movements for 2014, is an update of the 2013 guidance given in January 2013.

View 2014 currency guidance


Keeping investors in touch

Download our iPad app now from the app store

AstraZeneca Investor Relations iPad app

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Notifications will keep you up to date with the most recent updates from AstraZeneca and synchronise to your device for reference.

Download and install from the iTunes store

Latest press releases

Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency
22 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses
14 January 2015
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
12 January 2015
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations   
19 December 2014
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
18 December 2014
AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis
11 December 2014
MOVENTIG® approved in the European Union for opioid-induced constipation
9 December 2014
Jury verdict favours AstraZeneca in Nexium antitrust litigation
5 December 2014
New Drug Application for IRESSA accepted by US Food and Drug Administration
2 December 2014
AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease
1 December 2014
MedImmune completes acquisition of Definiens
26 November 2014
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
25 November 2014

Share price

London
47.04 GBP
New York
71.44 USD
Stockholm
587.50 SEK

At 28-1-2015 16:10 GMT

Detailed share price


Stock symbol - AZN

On LSE, NYE and OMX